ANEMIA CORRECTION IN HIV-INFECTED PREGNANT WOMEN RECEIVING ANTIRETROVIRAL AGENTS
- Authors: SHIFMAN E.M1, KRUGLOVA L.V2, VARTANOV V.Y.2, KHUTORSKAYA N.N2, LAPTEVA I.V2
-
Affiliations:
- Peoples' Friendship University of Russia
- Interdistrict Perinatal Center, Clinical Hospital Five, Togliatti
- Issue: No 7 (2012)
- Pages: 30-35
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/246809
- ID: 246809
Cite item
Open Access
Access granted
Abstract
Objective. Based on complete blood count and on red blood cells morphology to reveal the nature of anemia in HIV-infected pregnant women receiving chemoprophylaxis, and determine ways of correction. Subjects and methods. Prospective control trial of 162 HIV- infected pregnant women, phase III were conducted in interregional perinatal center «Clinical hospital №5» (Tolyatty) from December 2009 to February 2012. 162 HIV-infected pregnant women were delivered with planned caesarian section in gestational age of 37-38 weeks. Study group received antiretroviral agents after 14 weeks of gestation. Antiretroviral agents were Kaletra (lopinavir + ritonavir), 0.4 g twice a day, Combivir (lamivudine + zidovudine) 0.45 g twice a day, nikavir (Phosphazide) 0.6 g twice a day, Epivir (lamivudine) 0.15 g twice a day. Control group were 139 uncomplicated pregnancies. Results. The paper analyzes 162 cases of surgical delivery in HIV-infected pregnant women. The nature of anemia is revealed on the basis of the data of complete blood count and red blood cells morphology. The correcting ways of this disease are defined. Recommendations for the prevention and treatment of anemia are given for HIV-infected patients receiving antiretroviral agents. Conclusions. Haematopoiesis disorder leads to depression of red blood cells development due to receiving antiretroviral agents primary Nucleoside Reverse Transcriptase Inhibitor among HIV-infected pregnant women. Combination of activators of erythropoiesis in association with iron and folic acid is pathogenically proved among HIV-infected pregnant women receiving chemoprophylaxis.
Keywords
Full Text
About the authors
E. M SHIFMAN
Peoples' Friendship University of Russia
Email: eshifman@mail.ru
L. V KRUGLOVA
Interdistrict Perinatal Center, Clinical Hospital Five, Togliatti
Email: likrugova@yandex.ru
V. Ya VARTANOV
Interdistrict Perinatal Center, Clinical Hospital Five, Togliatti
Email: vartan9@yandex.ru
N. N KHUTORSKAYA
Interdistrict Perinatal Center, Clinical Hospital Five, Togliatti
I. V LAPTEVA
Interdistrict Perinatal Center, Clinical Hospital Five, Togliatti
References
- European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J. Acquir. Immune Defic. Syndr. 2003; 32: 380-7.
- Genne D., Sudre P., Anwar D., Goehring C., Saaidia A., Hirschel B. Causes of macrocytosis in HIV infected patients not treated with zidovudine. Swiss HIV Cohort Study. J. Infect. 2000; 40(2): 160-3.
- Lorenzi P., Spicher V.M., Laubereau B., Hirchel B., Kind C., Rubin C. et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS. 1998; 12(18): F241-7.
- Mocroft A., Kirk O., Barton S.E., Dietrich M., Proenca R., Colebunders R. et al. Anemia is an independent predictive marker for clinical prognosis in HIV infected patients from across Europe. AIDS. 1999; 13(8): 943-50.
- Moore R.D., Forney D. Anemia in HIV infected patients receiving highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2002; 29(1): 54-7.
- Spivak J.L. Serum immunoreactive erythropoietin in health and disease. J. Perinat. Med. 1995; 23: 13-7.
- Walker R.E., Parker R.I., Kovacs J.A., Masur H., Lane H.C., Carleton S. et al. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine. Ann. Intern. Med. 1988; 108: 372—6.
Supplementary files
